Baylor Genetics Holdings, Inc.

Baylor Genetics Holdings, Inc. specializes in genetic testing solutions, providing essential insights for healthcare providers and researchers to facilitate personalized medicine and informed clinical decisions. Baylor Genetics Holdings, Inc. is engaged in advanced genetic testing services, having been founded in 1978 in Houston, US.

The company has participated in one significant deal, with its most recent funding round occurring on April 9, 2025. This round, known as LP Direct, raised USD 50. 00 mn from H. U.

Group Holdings, bringing the total amount raised to USD 50. 00 mn. Baylor Genetics offers a comprehensive suite of genetic testing solutions designed to provide insights for healthcare providers, researchers, and families. Their core product offerings include Whole Exome Sequencing, Whole Genome Sequencing, and Chromosomal Microarray Analysis, among others.

These advanced testing modalities are aimed at identifying genetic variations linked to various health conditions, enabling personalized medicine and informed clinical decisions. Baylor Genetics primarily serves a clientele that includes healthcare professionals, medical institutions, and research organizations, facilitating testing for rare diseases, prenatal conditions, and inherited disorders. The company markets its services in various geographical regions, including North America, Europe, and select markets in Asia, ensuring a broad reach for their innovative genetic testing solutions. Baylor Genetics operates on a transaction-based revenue model, providing genetic testing services directly to healthcare providers and institutions.

The company typically engages in business-to-business (B2B) transactions, facilitating laboratory testing requests through a streamlined ordering system. Clients utilize a digital platform to order tests, such as the GeneAware™ and Reproductive PreSeek™, and receive results that assist in patient management and decision-making. The revenue structure is supported by partnerships with healthcare providers, who rely on Baylor Genetics for high-quality, timely genetic testing services. Pricing plans for specific tests are determined based on the complexity and scope of the analysis required, allowing flexibility for various client needs while ensuring accessibility to cutting-edge genetic insights.

In April 2025, H. U. Group Holdings acquired an undisclosed stake in Baylor Genetics Holdings, Inc. for USD 50.

00 mn. This investment aims to strengthen Baylor Genetics' growth, support future IPO plans, and expand advanced genetic testing services globally. The company is actively designing new products to enhance its service offerings, with plans for launch in new geographic markets, focusing on regions in Asia and Europe by 2026. The recent funding will be instrumental in supporting these initiatives, facilitating the expansion of their advanced genetic testing capabilities and aligning with potential growth strategies.